Lazanda Fentanyl Nasal Spray Pre Radiofrequency Nerve Ablations(RFA) of Lumbar Facet Joints

Phase 4

Completed

Conditions: Minor Procedural Pain

Interventions: Drug: Lazanda

Registration Number: NCT02571634

Lead Sponsor: Defense and Veterans Center for Integrative Pain Management

Brief Summary: The purpose of this study is to evaluate the effectiveness, feasibility and safety of intranasal fentanyl (Lazanda) as an alternative to the current gold standard (diazepam) to produce anxiolysis and improve patient comfort during and after radiofrequency ablations of the lumbar facet joints. If this pilot study shows a positive effect and Lazanda is found to be feasible and safe for use during procedures, future larger scale studies can be done.

Detailed Description: The morning of the procedure/procedures the medication will be obtained from the omnicel by one of the qualified pain clinic study staff for the volunteers that have consented for that day. . It will be signed out on the designated form created for tracking and accountability purposes Patient consent for study participation will be confirmed.

Once in the procedure room a DVPRS (Defense and Veterans Pain Rating Scale) baseline pain score and POSS (Pasero Opioid-induced Sedation Scale) score will be assessed by a member of the research team. Baseline non-invasive blood pressure, heart rate, and oxygen saturation will be documented and continuous monitoring of these vital signs will commence by a provider credentialed by WAMC (Womack Army Medical Center) to perform anxiolysis with documentation every 15 minutes until discharge. A qualified RN (Registered Nurse), or physician will administer 100 mcg of Lazanda ten-fifteen minutes prior to the procedure The administration will be witnessed and confirmed on Appendix D. The unused 7 mcg will be wasted in a charcoal filled bag provided by the manufacturer and that bag will be disposed of per hospital policy. The waste will also be witnessed and noted. The Pasero Opioid-Induced Sedation Scale and a DVPRS pain score will be assessed every 15 minutes through the conclusion of the procedure and every 15 minutes up until discharge or for 1 hour post procedure whichever comes first. If naloxone is required during the procedure this will be noted as well. Any adverse or serious adverse events will be reported per regulatory regulations.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 23

Inclusion Criteria

Male and female patients ASA(American Society of Anesthesiologist physical classification system) I-III
18 years of age and older Referred for lumbar facet RFA (radio-frequency ablation) by Womack IPMC (Interdisciplinary Pain Management Center)

Exclusion Criteria

Known allergy to Fentanyl or naloxone
Diagnoses of allergic rhinitis with active rhinorrhea
Pregnant or Breastfeeding
Asthma or COPD (chronic obstructive pulmonary disease) that requires frequent rescue medications.
Hepatic insufficiency with abnormal liver enzymes
Noted decreased mental function
Heart rate under 50 or BP below 90 systolic and/or 60 diastolic
Myasthenia gravis diagnoses
Acute narrow angle glaucoma
Allergy to meperidine
On medications with a known dangerous drug interactions to Fentanyl

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Open label	Lazanda	Open label, no blinding, everyone receives Lazanda.

Primary Outcome Measures

Name	Time	Method
Safety and Tolerability as Measured by the Number of Adverse Events	24 hours	Adverse events will be recorded by a yes or no as to their occurence

Secondary Outcome Measures

Name	Time	Method
Patient Satisfaction Using a Likert Satisfaction Survey	24 hours	At 24 hour after the procedure a call was made asking the volunteer to provide a number on a scale to describe their satisfaction with their pain control and their overall satisfaction. A 5 point likert scale was used 1 = very satisfied, 2 satisfied, 3 neither satisfied nor dis-satisfied, 4 not satisfied and 5 very unsatisfied.
Adverse Events	24 hours	Volunteers are monitored closely with vs, and sedation levels and any adverse issues will be recorded.
Sedation Level Assessed by POSS Tool	Baseline, 15 min, 30 min, 45 min, discharge	At baseline, 15 minutes post medication receipt, 30 minutes , 45 minutes and at discharge a Pasero-Opioid Sedation Scale Score was obtained. This scale is to measure alertness and amount of sedation. POSS was the abbreviated term used for this scale. The guidelines for that scale include: S= sleeping easily aroused 1= alert and awake; 2= slightly drowsy easily aroused; 3= frequently drowsy, drifts off to sleep during conversation; 4= somnolent, minimal or no response
Pain Score Differences Using the DVPRS (Defense and Veterans Pain Rating Scale) Tool.	Baseline, 15 min, 30 min, 45 min, and discharge	DVPRS pain scores will be recorded baseline and at 15 minutes post dosing, 30 minutes, 45 minutes and discharge. The DVPRS is a pain scale utilizing color coding descriptive terms and faces to describe pain levels from 0 meaning no pain and 10 the most excruciating pain ever.